Press ReleasesCannaray Subsidiary Therismos Signs Partnership With Alliance Healthcare Deutschland, GEHE...

Cannaray Subsidiary Therismos Signs Partnership With Alliance Healthcare Deutschland, GEHE Pharma Handel, & Thier Cooperation Partners

-

THE cooperation family of Alphega and gesund leben is pleased to announce a strong partnership with their newest member, Therismos GmbH, the German subsidiary of Cannaray Ltd. Both pharmacy networks benefit equally from this innovative partnership, thus expanding their existing base of partnerships and being able to provide optimal patient care in the medical cannabis sector nationwide.

As a leading European cannabis company that includes both medical cannabis and CBD wellness brands, Therismos GmbH – the German subsidiary of Cannaray Ltd. – will supply high-quality medical cannabis products, which can now be obtained from all pharmacies in Germany via AHD and GEHE. The partnership also benefits the two pharmacy cooperations Alphega and gesund leben, with the deal including attractive purchasing conditions and discounts. Member pharmacies of both networks will also be able to complete a training program to provide patients with superior medical cannabis support, positioning themselves as local experts in the field.

“With Therismos GmbH, we now have a specialist at our side with whom our pharmacy partners can position themselves as experts in the field of medical cannabis for the benefit of their patients”, said Aline Seifert, CEO of Alliance Healthcare Deutschland and Managing Director of GEHE Pharma Handel about the latest partnership. Matthias Greutter, Country Manager Cooperation, adds: “We are very pleased that with Therismos GmbH, we have been able to win a unique partner for our cooperation family Alphega and gesund leben.”

Christian Naumann, Managing Director of Therismos GmbH, says: “We are also pleased to announce this progressive partnership with Alliance Healthcare Deutschland and GEHE Pharma Handel and their more than 4,000 cooperation partners in the ‘Alphega’ and ‘gesund leben’ network and to provide our established medical cannabis products in Germany. As a specialist in this rapidly growing sector, the pharmacy partners can already benefit from our product range today, while we are setting up the education programme in the coming weeks.”

Latest news

Germany Seeing Sense, High Tide Strikes Deal With Major German Player, European Expansion For Bedrocan, Danish Buy-Out, Greek First, £2m UK Hemp Boost

THE German Government’s refreshingly honest approach to drugs and addiction is being demonstrated with a focus on the harms...

European Cannabis Stocks Review: Akanda Announces ‘First Significant Revenue Above Initial Projections’, Jazz Pharma Reimbursement Recommendation & Kanabo Climbs

Akanda  Akanda has enjoyed a sharp recovery in its share price this week, seeing its value return to levels not...

15% Of European Consumers Have Tried CBD, But Industry Held Back By ‘High Turnover Rate’ Of Users

THE European CBD market is set to see a ‘massive influx’ of previous and new consumers to the market...

Malta’s Pioneering Legal Cannabis Club Framework Announced, But Concerns Raised Licence Fees Could Push Many To Black Market

ON Friday (January 27) the Maltese Authority for the Responsible Use of Cannabis (ARUC) announced new guidelines set to...

Cannovum AG Establishes Cultivation Alliance For Germany

PRESS RELEASE CANNOVUM AG is currently founding the premier cultivation alliance for recreational cannabis in Germany. The aim of the...

Jazz Pharmaceuticals Receives NICE Recommendation For The Reimbursement Of Epidyolex (Cannabidiol) For The Treatment Of Seizures Associated With Tuberous Sclerosis Complex In England

PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals ("GW"; now...

Must read

You might also likeRELATED
Recommended to you